Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages CD16a (Fc gamma receptor IIIa) on NK cells/macrophages to trigger ADCC and phagocytosis, killing CD20+ cells (and also induces direct caspase-independent death of CD20+ cells). CD16a-expressing cells are effectors, not killed.